



SUGGESTED FORMULA

MISOPROSTOL 0.0024% DIPHENHYDRAMINE 0.5%

DEOXY-D-GLUCOSE 0.2%

LIDOCAINE 1% ORAL RINSE

Version number: 1.0 Volume: 100 mL

Misoprostol 200mcg tablets (commercial) 12 Tablets Diphenydramine Hydrochloride, USP (DI160) 0.5 g2-Deoxy-d-glucose, Reagent (DE103) 0.2 gLidocaine Hydrochloride, Monohydrate USP (LI103) 1.0 g Glycerin, (Natural) USP (G1016) 5 mL Flavor, (choice liquid water soluble) 2 mL Purified Water, USP (W1014) 50 mL Syrup, NF (SY105) QS to 100 mL

SUGGESTED COMPOUNDING PROCEDURES

- 1. Use one bottle method calibrate bottle to final volume with purified water
- 2. Triturate tablets and powders to fine powder
- 3. Transfer step 2 to bottle
- 4. Add flavor, glycerin and water to step 3
- 5. Add simple syrup and QS to final volume shake well.
- 6. Suggested quality assessments:
 - a. Uniform mixture
 - b. Color
 - c. Label (s) Shake well, refrigerate, BUD

Store in air-tight container.

Store Refrigerated

Warning - Do not use in pregnant patients; caution with females handling this material.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use Date should be assigned as directed by the current USP <795> Standards

This preparation should be prepared in a vertical airflow hood in a biological safety cabinet or barrier isolator. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

Precautions

Hazardous drugs should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a biological safety cabinet or compounding aseptic containment isolator. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein. 05/15rd

Phone: 800.370.6231 | Fax: 732.608.5420 | Internet: SpectrumRx.com | Email: sales@spectrumrx.com © 2015 Spectrum Pharmacy Products. All rights reserved.